Cannabinoid Nanoplatform Treats Knee Osteoarthritis
Summary
USPTO published patent application US20260108539A1, filed October 21, 2024 by Cannabis Bioscience International Holdings Inc, covering a cannabinoid-based nanoplatform composition and methods for treating knee osteoarthritis via intra-articular injection. The composition combines phytocannabinoids CBG and CBC with hyaluronic acid, type II collagen, and calcium gluconate, targeting joint pain, stiffness, reduced mobility, inflammation, and cartilage degeneration in osteoarthritis patients. The nanoemulsification-based production process creates particles smaller than 200 nm with pre-sterilization via membrane filtration.
“This document presents a novel composition and method for treating osteoarthritis using a cannabinoid-based nanoplatform administered via intra-articular injection.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
USPTO published patent application US20260108539A1, filed by Cannabis Bioscience International Holdings Inc on October 21, 2024, covering a novel cannabinoid-based nanoplatform composition for treating knee osteoarthritis. The invention combines phytocannabinoids CBG and CBC with hyaluronic acid, type II collagen, and calcium gluconate in a nanoemulsified formulation designed for enhanced bioavailability and controlled release in the synovial space. The application describes therapeutic mechanisms including CB1/CB2 receptor interaction, cytokine modulation, NF-κB inhibition, and TRPV1 activation for anti-inflammatory effects. No regulatory compliance obligations are created by this publication; the application remains pending examination.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Cannabinoid Based Nanoplatform Composition and Methods for treating knee osteoarthritis
Application US20260108539A1 Kind: A1 Apr 23, 2026
Assignee
Cannabis Bioscience International Holdings Inc
Inventors
Rosangel del Valle Andrades Fuentes, Nancy Paola Duarte Delgado, Nancy Rodrigues Das Fontes, Stephanie Dona Hartmann, Ana Maria Maldonado Vacca, Maria Angelica Clavijo Romero
Abstract
This document presents a novel composition and method for treating osteoarthritis using a cannabinoid-based nanoplatform administered via intra-articular injection. The composition includes phytocannabinoids such as CBG and CBC, along with hyaluronic acid, type II collagen, and calcium gluconate, embedded within a nanoplatform designed to enhance bioavailability and ensure controlled release in the synovial space. Tailored for osteoarthritis patients, the treatment alleviates joint pain, stiffness, reduced mobility, inflammation, sensations of friction, muscle weakness, and joint deformity. Cannabinoids act through multiple mechanisms, including interaction with CB1 and CB2 receptors, cytokine modulation, inhibition of NF-κB, and activation of the TRPV1 receptor, providing a potent anti-inflammatory effect. The formulation aims to halt cartilage degeneration, reduce pain, and slow osteoarthritis progression. The production process uses nanoemulsification techniques to create particles smaller than 200 nm, with pre-sterilization through membrane filtration, ensuring both efficacy and safety.
CPC Classifications
A61K 31/658 A61K 9/1075 A61K 31/216 A61K 31/726 A61K 38/014 A61K 47/14
Filing Date
2024-10-21
Application No.
18922127
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.